NWR Virtual Healthcare Conference
MELBOURNE, AUSTRALIA 20 March 2024: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that its CEO and MD, Dr Michael Baker, will today present at the NWR Virtual Healthcare Conference.
Dr Baker will present key pre‐clinical data for Arovella’s iNKT cell therapy platform and describe how Arovella’s technology provides important advantages over existing T‐cell therapies and has the potential to be applied to both blood cancers and solid tumours.
